Adult growth hormone deficiency: clinical advances and approaches to improve adherence

References

• Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152–177.
   PubMed Web of Science ®Google Scholar
• Ramos-Levi AM, Marazuela M. Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine. 2018;60:203–218.
   PubMed Web of Science ®Google Scholar
• Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98:1466–1475.
   PubMed Web of Science ®Google Scholar
• Hammarstrand C, Ragnarsson O, Hallen T, et al. Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol. 2017;177:251–256.
   PubMed Web of Science ®Google Scholar
• Jasim S, Alahdab F, Ahmed AT, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine. 2017;56:33–42.
   PubMed Web of Science ®Google Scholar
• Olsson DS, Nilsson AG, Bryngelsson IL, et al. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab. 2015;100:2651–2658.
   PubMed Web of Science ®Google Scholar
• Pappachan JM, Raskauskiene D, Kutty VR, et al. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015;100:1405–1411.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Koltowska-Haggstrom M, Cook DM, et al. Primary treatment regimen and diabetes insipidus as predictors of health outcomes in adults with childhood-onset craniopharyngioma. J Clin Endocrinol Metab. 2014;99:1227–1235.
   PubMed Web of Science ®Google Scholar
• Yuen KCJ, Mattsson AF, Burman P, et al. Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement. J Clin Endocrinol Metab. 2018;103:768–777.
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:2330–2340.
   PubMed Web of Science ®Google Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587–1609.
   PubMed Web of Science ®Google Scholar
• Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab. 2003;88:3682–3689.
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Claessen KM, Roelfsema F, et al. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. Eur J Endocrinol. 2013;169:R1–14.
   PubMed Web of Science ®Google Scholar
• Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168:745–753.
   PubMed Web of Science ®Google Scholar
• Elbornsson M, Horvath A, Gotherstrom G, et al. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2017;176:99–109.
   PubMed Web of Science ®Google Scholar
• Mo D, Blum WF, Rosilio M, et al. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab. 2014;99:4581–4588.
   PubMed Web of Science ®Google Scholar
• Puche JE, Castilla-Cortazar I. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med. 2012;10:224.
   PubMed Web of Science ®Google Scholar
• Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002;87:477–485.
   PubMed Web of Science ®Google Scholar
• Clayton PE, Cuneo RC, Juul A, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 2005;152:165–170.
   PubMed Web of Science ®Google Scholar
• Cook DM, Yuen KC, Biller BM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009;15(Suppl 2):1–29.
   PubMedGoogle Scholar
• Pekic S, Popovic V. Diagnosis of endocrine disease: expanding the cause of hypopituitarism. Eur J Endocrinol. 2017;176:R269–R282.
   PubMed Web of Science ®Google Scholar
• Tanriverdi F, Kelestimur F. Classical and non-classical causes of GH deficiency in adults. Best Pract Res Clin Endocrinol Metab. 2017;31:3–11.
   PubMed Web of Science ®Google Scholar
• Gordon MB, Levy RA, Gut R, et al. Trends in growth hormone stimulation testing and growth hormone dosing in adult growth hormone deficiency patients: results from the ANSWER program. Endocr Pract. 2016;22:396–405.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Biller BM, Molitch ME, et al. Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94:2702–2707.
   PubMed Web of Science ®Google Scholar
• Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002;87:2067–2079.
   PubMed Web of Science ®Google Scholar
• Berg C, Meinel T, Lahner H, et al. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol. 2010;162:477–482.
   PubMed Web of Science ®Google Scholar
• Conceicao FL, da Costa E Silva A, Leal Costa AJ, et al. Glucagon stimulation test for the diagnosis of GH deficiency in adults. J Endocrinol Invest. 2003;26:1065–1070.
   PubMed Web of Science ®Google Scholar
• Gomez JM, Espadero RM, Escobar-Jimenez F, et al. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol (Oxf). 2002;56:329–334.
   PubMed Web of Science ®Google Scholar
• Utz AL, Yamamoto A, Sluss P, et al. Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion. J Clin Endocrinol Metab. 2008;93:4033–4040.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Tritos NA, Samson SL, et al. American association of clinical endocrinologists and American college of endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract. 2016;22:1235–1244.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Biller BM, Katznelson L, et al. Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. Pituitary. 2013;16:220–230.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Drug trials snapshot: macrilen; [ cited 2019 May]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-marcrilen
   Google Scholar
• European Medicines Agency. [ cited 2019 May]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/macimorelin-aeterna-zentaris
   Google Scholar
• Piccoli F, Degen L, MacLean C, et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab. 2007;92:1814–1820.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Swerdloff R, Wang C, et al. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2013;98:2422–2429.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a diagnostic test for adult growth hormone deficiency. J Clin Endocrinol Metab. 2018;103:3083–3093.
   PubMed Web of Science ®Google Scholar
• Diez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks. Int J Mol Sci. 2018;19:893.
   Web of Science ®Google Scholar
• Chikani V, Cuneo RC, Hickman I, et al. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf). 2016;85:660–668.
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Sathyapalan T, Javed Z, et al. Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency. Front Endocrinol (Lausanne). 2018;9:56.
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Windram JD, Sathyapalan T, et al. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res. 2017;45:1708–1719.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Frystyk J, White DK, et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf). 2005;63:428–436.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Roberts CT Jr., Frystyk J, et al. Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency. J Clin Endocrinol Metab. 2014;99:E1862–1869.
   PubMed Web of Science ®Google Scholar
• Penta L, Cofini M, Lucchetti L, et al. Growth hormone (GH) therapy during the transition period: should we think about early retesting in patients with idiopathic and isolated GH deficiency? Int J Environ Res Public Health. 2019;16:307.
   Web of Science ®Google Scholar
• Attanasio AF, Shavrikova E, Blum WF, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab. 2004;89:4857–4862.
   PubMed Web of Science ®Google Scholar
• Clayton P, Gleeson H, Monson J, et al. Growth hormone replacement throughout life: insights into age-related responses to treatment. Growth Horm IGF Res. 2007;17:369–382.
   PubMed Web of Science ®Google Scholar
• Conway GS, Szarras-Czapnik M, Racz K, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol. 2009;160:899–907.
   PubMed Web of Science ®Google Scholar
• Appelman-Dijkstra NM, Claessen KM, Hamdy NA, et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden cohort study. Clin Endocrinol (Oxf). 2014;81:727–735.
   PubMed Web of Science ®Google Scholar
• Olsson DS, Trimpou P, Hallen T, et al. Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. Eur J Endocrinol. 2017;176:67–75.
   PubMed Web of Science ®Google Scholar
• Gasco V, Prodam F, Grottoli S, et al. GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses. Eur J Endocrinol. 2013;168:R55–66.
   PubMed Web of Science ®Google Scholar
• Spielhagen C, Schwahn C, Moller K, et al. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res. 2011;21:1–10.
   PubMed Web of Science ®Google Scholar
• Svensson J, Fowelin J, Landin K, et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:2121–2127.
   PubMed Web of Science ®Google Scholar
• Filipsson Nystrom H, Barbosa EJ, Nilsson AG, et al. Discontinuing long-term GH replacement therapy–a randomized, placebo-controlled crossover trial in adult GH deficiency. J Clin Endocrinol Metab. 2012;97:3185–3195.
   PubMed Web of Science ®Google Scholar
• Newman CB, Carmichael JD, Kleinberg DL. Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary. 2015;18:297–305.
   PubMed Web of Science ®Google Scholar
• Biller BM, Sesmilo G, Baum HB, et al. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000;85:970–976.
   PubMed Web of Science ®Google Scholar
• Gotherstrom G, Bengtsson BA, Bosaeus I, et al. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol. 2007;156:55–64.
   PubMed Web of Science ®Google Scholar
• Allo Miguel G, Serraclara Pla A, Partida Munoz ML, et al. Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center. Ther Adv Endocrinol Metab. 2016;7:93–100.
   PubMed Web of Science ®Google Scholar
• Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014;99:852–860.
   PubMed Web of Science ®Google Scholar
• Xue P, Wang Y, Yang J, et al. Effects of growth hormone replacement therapy on bone mineral density in growth hormone deficient adults: a meta-analysis. Int J Endocrinol. 2013;2013:216107.
   PubMedGoogle Scholar
• Sommer G, Gianinazzi ME, Kuonen R, et al. Health-related quality of life of young adults treated with recombinant human growth hormone during childhood. PLoS One. 2015;10:e0140944.
   PubMedGoogle Scholar
• Koltowska-Haggstrom M. Quality of life and growth hormone deficiency in adult patients in clinical evaluation and health economic assessment. Pediatr Endocrinol Diabetes Metab. 2009;15:203–209.
   PubMedGoogle Scholar
• Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the study of health in Pomerania. Eur J Endocrinol. 2009;160:17–24.
   PubMed Web of Science ®Google Scholar
• Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166:13–20.
   PubMed Web of Science ®Google Scholar
• Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004;89:1684–1693.
   PubMed Web of Science ®Google Scholar
• Brod M, Beck JF, Hojbjerre L, et al. Assessing the impact of growth hormone deficiency (GHD) in adults: interpreting change of the treatment-related impact measure-adult growth hormone deficiency (TRIM-AGHD). Pharmacoecon Open. 2019;3:71–80.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Gola M, Karamouzis I, et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH–an update. J Clin Endocrinol Metab. 2014;99:18–29.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Fukuoka H, Iguchi G, et al. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency. Growth Horm IGF Res. 2014;24:174–179.
   PubMed Web of Science ®Google Scholar
• Ziagaki A, Blaschke D, Haverkamp W, et al. Long-term growth hormone (GH)-replacement of adult GH-deficiency (GHD) benefits the heart. Eur J Endocrinol. 2019;181:79–91.
   PubMed Web of Science ®Google Scholar
• Maison P, Griffin S, Nicoue-Beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89:2192–2199.
   PubMed Web of Science ®Google Scholar
• Deepak D, Daousi C, Javadpour M, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res. 2010;20:220–225.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133:111–122.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng X, Xie X, et al. Correlation of increased serum adipsin with increased cardiovascular risks in adult patients with growth hormone deficiency. Endocr Pract. 2019;25:446–453.
   PubMed Web of Science ®Google Scholar
• Andiran N, Yordam N. TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Horm IGF Res. 2007;17:149–153.
   PubMed Web of Science ®Google Scholar
• Joaquin C, Aguilera E, Granada ML, et al. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol. 2008;158:483–490.
   PubMed Web of Science ®Google Scholar
• Scacchi M, Valassi E, Pincelli AI, et al. Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest. 2006;29:899–904.
   PubMed Web of Science ®Google Scholar
• Setola E, Monti LD, Lanzi R, et al. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism. 2008;57:1685–1690.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3888–3921.
   PubMed Web of Science ®Google Scholar
• Kokshoorn NE, Biermasz NR, Roelfsema F, et al. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol. 2011;164:657–665.
   PubMed Web of Science ®Google Scholar
• Franco C, Johannsson G, Bengtsson BA, et al. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency. J Clin Endocrinol Metab. 2006;91:4408–4414.
   PubMed Web of Science ®Google Scholar
• Vilar L, Vilar CF, Lyra R, et al. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20:22–32.
   PubMed Web of Science ®Google Scholar
• Brod M, Pohlman B, Hojbjerre L, et al. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Res Notes. 2014;7:813.
   PubMedGoogle Scholar
• Devin JK, Blevins LS Jr., Verity DK, et al. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2007;92:3633–3639.
   PubMed Web of Science ®Google Scholar
• Kvasnicka J, Marek J, Kvasnicka T, et al. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf). 2000;52:543–548.
   PubMed Web of Science ®Google Scholar
• Sartorio A, Cattaneo M, Bucciarelli P, et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes. 2000;108:486–492.
   PubMed Web of Science ®Google Scholar
• Steiger A. Sleep and endocrinology. J Intern Med. 2003;254:13–22.
   PubMed Web of Science ®Google Scholar
• Spiegel K, Leproult R, Colecchia EF, et al. Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am J Physiol Regul Integr Comp Physiol. 2000;279:R874–883.
   PubMed Web of Science ®Google Scholar
• Obal F Jr., Floyd R, Kapas L, et al. Effects of systemic GHRH on sleep in intact and hypophysectomized rats. Am J Physiol. 1996;270:E230–237.
   PubMedGoogle Scholar
• Marshall L, Molle M, Boschen G, et al. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J Clin Endocrinol Metab. 1996;81:1009–1013.
   PubMed Web of Science ®Google Scholar
• Perras B, Marshall L, Kohler G, et al. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology. 1999;24:743–757.
   PubMed Web of Science ®Google Scholar
• Copinschi G, Nedeltcheva A, Leproult R, et al. Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2010;95:2195–2202.
   PubMed Web of Science ®Google Scholar
• Nolte W, Radisch C, Rodenbeck A, et al. Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. Clin Endocrinol (Oxf). 2002;56:805–810.
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Oertel H, Murck H, et al. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Psychoneuroendocrinology. 2005;30:29–37.
   PubMed Web of Science ®Google Scholar
• Peker Y, Svensson J, Hedner J, et al. Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6 months of GH replacement therapy. Clin Endocrinol (Oxf). 2006;65:98–105.
   PubMed Web of Science ®Google Scholar
• Ismailogullari S, Tanriverdi F, Kelestimur F, et al. Sleep architecture in Sheehan’s syndrome before and 6 months after growth hormone replacement therapy. Psychoneuroendocrinology. 2009;34:212–219.
   PubMed Web of Science ®Google Scholar
• Morselli LL, Nedeltcheva A, Leproult R, et al. Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin. Eur J Endocrinol. 2013;168:763–770.
   PubMed Web of Science ®Google Scholar
• Hasan W, Cowen T, Barnett PS, et al. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Auton Neurosci. 2001;89:100–109.
   PubMed Web of Science ®Google Scholar
• Borlu M, Tanriverdi F, Koc CA, et al. The effects of severe growth hormone deficiency on the skin of patients with Sheehan’s syndrome. J Eur Acad Dermatol Venereol. 2007;21:199–204.
   PubMed Web of Science ®Google Scholar
• Tanriverdi F, Borlu M, Atmaca H, et al. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study. Clin Endocrinol (Oxf). 2006;65:579–585.
   PubMed Web of Science ®Google Scholar
• Medeiros A, Siegel Watkins E. Live longer better: the historical roots of human growth hormone as anti-aging medicine. J Hist Med Allied Sci. 2018;73:333–359.
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. J Clin Endocrinol Metab. 2014;99:409–411.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Pezzullo S, Palmieri V, et al. Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. Thromb Res. 2010;126:e434–438.
   PubMed Web of Science ®Google Scholar
• Miljic D, Miljic P, Doknic M, et al. Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency. Growth Horm IGF Res. 2013;23:243–248.
   PubMed Web of Science ®Google Scholar
• Cakir I, Tanriverdi F, Karaca Z, et al. Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm IGF Res. 2012;22:17–21.
   PubMed Web of Science ®Google Scholar
• Smith JC, Lane HA, Lewis J, et al. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. J Clin Endocrinol Metab. 2003;88:2152–2156.
   PubMed Web of Science ®Google Scholar
• van Bunderen CC, Lips P, Kramer MH, et al. Comparison of low-normal and high-normal IGF-1 target levels during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency. Eur J Intern Med. 2016;31:88–93.
   PubMed Web of Science ®Google Scholar
• van Bunderen CC, Deijen JB, Drent ML. Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency. Health Qual Life Outcomes. 2018;16:135.
   PubMed Web of Science ®Google Scholar
• Attanasio AF, Jung H, Mo D, et al. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab. 2011;96:2255–2261.
   PubMed Web of Science ®Google Scholar
• Luger A, Mattsson AF, Koltowska-Haggstrom M, et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care. 2012;35:57–62.
   PubMed Web of Science ®Google Scholar
• Weber MM, Biller BM, Pedersen BT, et al. The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet((R)) international outcome study. Clin Endocrinol (Oxf). 2017;86:192–198.
   PubMed Web of Science ®Google Scholar
• Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res. 2015;25:149–157.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 2002;360:273–277.
   PubMed Web of Science ®Google Scholar
• Popovic V, Mattsson AF, Gaillard RC, et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer international metabolic database). J Clin Endocrinol Metab. 2010;95:4449–4454.
   PubMed Web of Science ®Google Scholar
• Child CJ, Zimmermann AG, Woodmansee WW, et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the hypopituitary control and complications study. Eur J Endocrinol. 2011;165:217–223.
   PubMed Web of Science ®Google Scholar
• Child CJ, Conroy D, Zimmermann AG, et al. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the hypopituitary control and complications study. Eur J Endocrinol. 2015;172:779–790.
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, Boguszewski M. Growth hormone’s links to cancer. Endocr Rev. 2019;40:558–574.
   PubMed Web of Science ®Google Scholar
• Jasim S, Alahdab F, Ahmed AT, et al. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. Endocrine. 2017;56:267–278.
   PubMed Web of Science ®Google Scholar
• Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012;166:1069–1077.
   PubMed Web of Science ®Google Scholar
• van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the dutch national registry of growth hormone treatment in adults. J Clin Endocrinol Metab. 2011;96:3151–3159.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou Q, Li Y, et al. Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: a meta-analysis. Oncotarget. 2016;7:81862–81869.
   PubMedGoogle Scholar
• Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol. 2001;19:480–487.
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2002;87:3136–3141.
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494–3498.
   PubMed Web of Science ®Google Scholar
• Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr. 2006;95:1284–1290.
   PubMed Web of Science ®Google Scholar
• Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr. 2010;157:265–270.
   PubMed Web of Science ®Google Scholar
• Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2014;99:2030–2037.
   PubMed Web of Science ®Google Scholar
• Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:2761–2784.
   PubMed Web of Science ®Google Scholar
• Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174:P1–9.
   PubMed Web of Science ®Google Scholar
• Pekic S, Stojanovic M, Popovic V. Controversies in the risk of neoplasia in GH deficiency. Best Pract Res Clin Endocrinol Metab. 2017;31:35–47.
   PubMed Web of Science ®Google Scholar
• Barton DE, Foellmer BE, Wood WI, et al. Chromosome mapping of the growth hormone receptor gene in man and mouse. Cytogenet Cell Genet. 1989;50:137–141.
   PubMedGoogle Scholar
• Godowski PJ, Leung DW, Meacham LR, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A. 1989;86:8083–8087.
   PubMed Web of Science ®Google Scholar
• Sobrier ML, Duquesnoy P, Duriez B, et al. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett. 1993;319:16–20.
   PubMed Web of Science ®Google Scholar
• Urbanek M, Russell JE, Cooke NE, et al. Functional characterization of the alternatively spliced, placental human growth hormone receptor. J Biol Chem. 1993;268:19025–19032.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, Essioux L, Teinturier C, et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36:720–724.
   PubMed Web of Science ®Google Scholar
• Gibney J, Johannsson G. Long-term monitoring of insulin-like growth factor I in adult growth hormone deficiency: a critical appraisal. Horm Res. 2004;62(Suppl 1):66–72.
   PubMedGoogle Scholar
• Pawlikowska-Haddal A, Cohen P, Cook DM. How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children? Pituitary. 2012;15:126–134.
   PubMed Web of Science ®Google Scholar
• Barbosa EJ, Glad CA, Nilsson AG, et al. Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. Eur J Endocrinol. 2012;167:353–362.
   PubMed Web of Science ®Google Scholar
• Barbosa EJ, Koranyi J, Filipsson H, et al. Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. Eur J Endocrinol. 2010;162:869–878.
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen U, Brabant G, Maiter D, et al. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. Eur J Endocrinol. 2013;168:733–743.
   PubMed Web of Science ®Google Scholar
• Meyer S, Schaefer S, Stolk L, et al. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Pharmacogenomics. 2009;10:1599–1608.
   PubMed Web of Science ®Google Scholar
• Moyes VJ, Walker DM, Owusu-Antwi S, et al. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults. Clin Endocrinol (Oxf). 2010;72:807–813.
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, van der Straaten T, Baak-Pablo R, et al. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab. 2008;93:2828–2834.
   PubMed Web of Science ®Google Scholar
• Adetunji OR, MacFarlane IA, Javadpour M, et al. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. Eur J Endocrinol. 2009;161:541–546.
   PubMed Web of Science ®Google Scholar
• Andujar-Plata P, Fernandez-Rodriguez E, Quinteiro C, et al. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency. Pituitary. 2015;18:101–107.
   PubMed Web of Science ®Google Scholar
• Barbosa EJ, Palming J, Glad CA, et al. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J Clin Endocrinol Metab. 2009;94:639–644.
   PubMed Web of Science ®Google Scholar
• Glad CA, Barbosa EJ, Filipsson Nystrom H, et al. SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults. Eur J Endocrinol. 2014;170:101–107.
   PubMed Web of Science ®Google Scholar
• Giavoli C, Ferrante E, Profka E, et al. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. Eur J Endocrinol. 2010;163:361–368.
   PubMed Web of Science ®Google Scholar
• Bianchi A, Giampietro A, Tartaglione L, et al. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: role of GH receptor polymorphism. J Neuroendocrinol. 2019;31:e12692.
   PubMed Web of Science ®Google Scholar
• Fisher G, Acerini L. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Pædiatr. 2013;79:189.
   PubMed Web of Science ®Google Scholar
• Graham S, Graham S, Weinman J, et al. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90:221–227.
   PubMed Web of Science ®Google Scholar
• Rosenfeld G, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14:143–154.
   PubMedGoogle Scholar
• Kremidas D, Wisniewski T, Divino VM, et al. Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs. 2013;28:55–63.
   PubMed Web of Science ®Google Scholar
• Abdi L, Sahnoun-Fathallah M, Morange I, et al. A monocentric experience of growth hormone replacement therapy in adult patients. Ann Endocrinol (Paris). 2014;75:176–183.
   PubMed Web of Science ®Google Scholar
• Auer MK, Stieg MR, Hoffmann J, et al. Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? Clin Endocrinol (Oxf). 2016;84:862–869.
   PubMed Web of Science ®Google Scholar
• Mancini A, Vergani E, Bruno C, et al. Relevance of adherence monitoring in adult patients with growth hormone deficiency under replacement therapy: preliminary monocentric data with EasyPodTM Connect. Front Endocrinol. 2019;10:416.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Hunt P, Manning P, et al. Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults. Clin Endocrinol (Oxf). 2015;83:85–90.
   PubMed Web of Science ®Google Scholar
• Mohseni S, Heydari Z, Qorbani M, et al. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31:13–20.
   PubMed Web of Science ®Google Scholar
• Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93:147–148.
   PubMed Web of Science ®Google Scholar
• Lass N, Reinehr T. Low treatment adherence in pubertal children treated with thyroxin or growth hormone. Horm Res Paediatr. 2015;84:240–247.
   PubMed Web of Science ®Google Scholar
• Kappelgaard A-M, Metzinger CP, Schnabel D. A web-based survey assessing the impact of storage flexibility on the daily life of patients and caregivers administering growth hormone. Expert Rev Med Devices. 2015;12:517–527.
   PubMed Web of Science ®Google Scholar
• Bagnasco F, Di Iorgi N, Roveda A, et al. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. 2017;23:929–941.
   PubMed Web of Science ®Google Scholar
• Haverkamp F, Gasteyger C. A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ. 2011;14:448–457.
   PubMedGoogle Scholar
• Bhosle M, Klingman D, Aagren M, et al. Human growth hormone treatment: synthesis of literature on product delivery systems and administration practices. J Spec Pediatr Nurs. 2011;16:50–63.
   PubMed Web of Science ®Google Scholar
• Llahana S, Marland A, Pantovic M, et al. Hypopituitarism and growth hormone deficiency in adults. In: Llahana S, Follin C, Yedinak C, et al., editors. Advanced practice in endocrinology nursing. Cham: Springer International Publishing; 2019. p. 469–494.
   Google Scholar
• Spoudeas HA, Bajaj P, Sommerford N. Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: comparing jet-delivery and needle-based devices. Patient Prefer Adherence. 2014;8:1255–1263.
   PubMed Web of Science ®Google Scholar
• Michaelidou M, Whitten S, Bajaj P, et al. Improved adherence and growth outcomes with jet-delivered growth hormone. J Pediatr Endocrinol Metab. 2019;32:207–213.
   PubMed Web of Science ®Google Scholar
• Bozzola M, Colle M, Halldin-Stenlid M, et al. Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents. BMC Endocr Disord. 2011;11:4.
   PubMed Web of Science ®Google Scholar
• Koledova E, Stoyanov G, Ovbude L, et al. Adherence and long-term growth outcomes: results from the easypod(™) connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect. 2018;7:914–923.
   PubMed Web of Science ®Google Scholar
• Centonze C, Guzzetti C, Orlando G, et al. Adherence to growth hormone (GH) therapy in naïve to treatment GH-deficient children: data of the Italian cohort from the easypod connect observational study (ECOS). J Endocrinol Invest. 2019;42:1241–1244.
   PubMedGoogle Scholar
• Pfützner A, Hartmann K, Winter F, et al. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. Clin Ther. 2010;32:1918–1934.
   PubMed Web of Science ®Google Scholar
• Cooper V, Metcalf L, Versnel J, et al. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026.
   PubMed Web of Science ®Google Scholar
• Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826–834.
   PubMed Web of Science ®Google Scholar
• Linn AJ, van Weert JC, van Dijk L, et al. The value of nurses’ tailored communication when discussing medicines: exploring the relationship between satisfaction, beliefs and adherence. J Health Psychol. 2016;21:798–807.
   PubMed Web of Science ®Google Scholar
• Wickramasuriya BP, Casey A, Akhtar S, et al. Factors determining patient choice of device for GH therapy. Horm Res. 2006;65:18–22.
   PubMed Web of Science ®Google Scholar
• Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174:C1–8.
   PubMed Web of Science ®Google Scholar
• Hoybye C, Cohen P, Hoffman AR, et al. Status of long-acting-growth hormone preparations–2015. Growth Horm IGF Res. 2015;25:201–206.
   PubMed Web of Science ®Google Scholar
• Sprogoe K, Mortensen E, Karpf DB, et al. The rationale and design of TransCon growth hormone for the treatment of growth hormone deficiency. Endocr Connect. 2017;6:R171–R181.
   PubMed Web of Science ®Google Scholar
• Lippe B, Frasier SD, Kaplan SA. Use of growth hormone-gel. Arch Dis Child. 1979;54:609–613.
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Kim J, Savoy C, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab. 2006;91:2926–2930.
   PubMed Web of Science ®Google Scholar
• Biller BM, Ji HJ, Ahn H, et al. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab. 2011;96:1718–1726.
   PubMed Web of Science ®Google Scholar
• Biller BM, Ji HJ, Ahn H, et al. Twelve-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. Pituitary. 2013;16:311–318.
   PubMed Web of Science ®Google Scholar
• Hwang JS, Lee HS, Chung WY, et al. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency. Eur J Endocrinol. 2013;169:179–185.
   PubMed Web of Science ®Google Scholar
• Khadilkar V, Radjuk KA, Bolshova E, et al. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab. 2014;99:126–132.
   PubMed Web of Science ®Google Scholar
• Peter F, Bidlingmaier M, Savoy C, et al. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab. 2012;97:400–407.
   PubMed Web of Science ®Google Scholar
• Peter F, Savoy C, Ji HJ, et al. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol. 2009;160:349–355.
   PubMed Web of Science ®Google Scholar
• Roemmler J, Gockel A, Otto B, et al. Effects on metabolic variables after 12-month treatment with a new once-a-week sustained-release recombinant growth hormone (GH: LB03002) in patients with GH deficiency. Clin Endocrinol (Oxf). 2012;76:88–95.
   PubMed Web of Science ®Google Scholar
• Hou L, Chen ZH, Liu D, et al. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Devel Ther. 2016;10:13–21.
   PubMed Web of Science ®Google Scholar
• Luo X, Hou L, Liang L, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017;177:195–205.
   PubMed Web of Science ®Google Scholar
• Battelino T, Rasmussen MH, De Schepper J, et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87:350–358.
   PubMed Web of Science ®Google Scholar
• Thygesen P, Andersen HS, Behrens C, et al. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone. Growth Horm IGF Res. 2017;35:8–16.
   PubMed Web of Science ®Google Scholar
• de Schepper J, Rasmussen MH, Gucev Z, et al. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. Eur J Endocrinol. 2011;165:401–409.
   PubMed Web of Science ®Google Scholar
• Rasmussen MH, Bysted BV, Anderson TW, et al. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab. 2010;95:3411–3417.
   PubMed Web of Science ®Google Scholar
• Rasmussen MH, Jensen L, Anderson TW, et al. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile. Clin Endocrinol (Oxf). 2010;73:769–776.
   PubMed Web of Science ®Google Scholar
• Sondergaard E, Klose M, Hansen M, et al. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab. 2011;96:681–688.
   PubMed Web of Science ®Google Scholar
• Touraine P, D’Souza GA, Kourides I, et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol. 2009;161:533–540.
   PubMed Web of Science ®Google Scholar
• Webster R, Xie R, Didier E, et al. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica. 2008;38:1340–1351.
   PubMed Web of Science ®Google Scholar
• Moore WV, Nguyen HJ, Kletter GB, et al. A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency. J Clin Endocrinol Metab. 2016;101:1091–1097.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Conway GS, Popovic V, et al. A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. J Clin Endocrinol Metab. 2013;98:2595–2603.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Barkay H, Rasamoelisolo M, et al. Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and caucasian subjects. Clin Pharmacol Drug Dev. 2017;6:331–342.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Sakov A, Rasamoelisolo M, et al. Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency. Eur J Endocrinol. 2015;173:541–551.
   PubMed Web of Science ®Google Scholar
• Chatelain P, Malievskiy O, Radziuk K, et al. A randomized phase 2 study of long-acting TransCon growth hormone vs daily growth hormone in childhood growth hormone deficiency. J Clin Endocrinol Metab. 2017;102:1673–1682.
   PubMed Web of Science ®Google Scholar
• Gilfoyle D, Mortensen E, Christoffersen ED, et al. A first-in-man phase 1 trial for long-acting TransCon growth hormone. Growth Horm IGF Res. 2018;39:34–39.
   PubMed Web of Science ®Google Scholar
• Hoybye C, Pfeiffer AF, Ferone D, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. 2017;6:129–138.
   PubMed Web of Science ®Google Scholar
• Thornton P, Hofman P, Maniatis A, et al. OR17-4 TransConTM growth hormone in the treatment of pediatric growth hormone deficiency: results of the phase 3 heiGHt trial. J Endocr Soc. 2019 Apr-May;3. DOI:10.1210/js.2019-OR2017-2014
   Google Scholar
• Kim NA, An IB, Lim HS, et al. Biophysical evaluation of hybrid Fc fusion protein of hGH to achieve basal buffer system. Int J Pharm. 2016;513:421–430.
   PubMedGoogle Scholar
• Fisher DM, Rosenfeld RG, Jaron-Mendelson M, et al. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr. 2017;87:324–332.
   PubMed Web of Science ®Google Scholar
• Hershkovitz O, Bar-Ilan A, Guy R, et al. In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm. 2016;13:631–639.
   PubMedGoogle Scholar
• Kramer WG, Jaron-Mendelson M, Koren R, et al. Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and caucasian adults. Clin Pharmacol Drug Dev. 2018;7:554–563.
   Web of Science ®Google Scholar
• Strasburger CJ, Vanuga P, Payer J, et al. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. 2017;176:283–294.
   PubMed Web of Science ®Google Scholar
• Zelinska N, Iotova V, Skorodok J, et al. Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in growth hormone deficient children. J Clin Endocrinol Metab. 2017;102:1578–1587.
   PubMed Web of Science ®Google Scholar
• Hoffman AR, Biller BM, Cook D, et al. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab. 2005;90:6431–6440.
   PubMed Web of Science ®Google Scholar
• Silverman BL, Blethen SL, Reiter EO, et al. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab. 2002;15(Suppl 2):715–722.
   PubMedGoogle Scholar
• Opko Biologics. [ cited 2019 July]. Available from: https://www.opkobiologics.com/pipeline/product-candidates/hgh-ctp/
   Google Scholar
• Yuen KCJ, Miller BS, Biller BMK. The current state of long-acting growth hormone preparations for growth hormone therapy. Curr Opin Endocrinol Diabetes Obes. 2018;25:267–273.
   PubMed Web of Science ®Google Scholar
• Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013;4:64.
   PubMedGoogle Scholar
• Johannsson G, Feldt-Rasmussen U, Hakonsson IH, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178:491–499.
   PubMed Web of Science ®Google Scholar
• Johannsson G, Gordon MB, Rasmussen MH, et al. SAT-LB074 Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency confirmed in a 53week REAL 1 trial extension. J Endocr Soc. 2019 Apr-May;3. DOI:10.1210/js.2019-SAT-LB2074
   Google Scholar